Sumo Group With its Substantial IP deserves a re-rating (Interview)

Sumo Group plc (LON:SUMO) is the topic of conversation when Bob Liao Technology Analyst at Zeus Capital joins DirectorsTalk. Bob explains how Sumo is positioned in terms of its intellectual property, the hidden sources of IP within the company and how this should translate into the company’s valuation.

Sumo Group’s businesses provide acclaimed development and design services to the video games and entertainment industries from studios in the UK, India, and Canada.

Sumo Digital, as the Group’s primary business, is one of the UK’s largest independent developers of AAA-rated video games, having studios in Sheffield, Newcastle, Nottingham, Leamington Spa, Warrington and Pune, India. The business has acquired two studios since IPO, which operate under their own names, BAFTA award-winning The Chinese Room in Brighton and Red Kite Games in Leeds. Sumo Digital provides turnkey and co-development solutions to a global blue-chip client base.

Atomhawk is a multi-award-winning visual design company, with studios in Newcastle and in Vancouver (Canada), servicing the games, film and visual effects industries.

Together, the Sumo Group plc delivers full-spectrum visual and development solutions, which include initial visual concepts, conceiving new products and game development involving all aspects of pre-production, production & development, as well as supporting games as a service.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Zeus Capital

    More articles like this

    Guild Esports sign two-year gaming chair sponsorship with Razer

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global teams organisation and lifestyle brand, has welcome Razer as the Company’s Official Gaming Chair Partner with the signing of a two-year global sponsorship deal. The total contract value, which

    Redde Northgate trading ahead of expectations

    Redde Northgate plc (LON:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle, has announced a trading update for the year ended 30 April 2022, ahead of its results for the year scheduled

    Inchcape

    Inchcape update on Russian operations

    Inchcape plc (LON:INCH) is deeply saddened by the ongoing conflict in Ukraine and the enormous humanitarian impact on all those affected. We share the hopes of the world for a peaceful resolution. In light of the current

    STRIX GROUP PLC ORD 1P

    Strix Group to conduct investor presentation on 31st March 2022

    Strix Group plc (LON:KETL), the global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components will be conducting an investor presentation covering their Full Year results to the period

    City of London Investment Group plc

    City of London Investment Group Barry Olliff increases holding

    City of London Investment Group plc (LON:CLIG), a leading specialist asset management group offering a range of institutional and retail products investing primarily in closed-end funds, stated that it has been notified that Stable View III LP,

    CentralNic

    CentralNic Group continue to beat expectations (Analyst Interview)

    CentralNic Group Plc (LON:CNIC) is the topic of conversation when Bob Liao Director and Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Bob provides us with an overview of VGL, explains how the acquisition fits in with CentalNic’s business,

    Guild Esports wins fifth major trophy

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global team organisation and lifestyle brand, has announced that it has won its fifth major trophy after its Fortnite pro-player, Henrik Mclean (‘Hen’), achieved first place in the prestigious Fortnite

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous